Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Other Events
Item 8.01
| Other Items. |
On April 19, 2017, Neuralstem, Inc. (the Company) updated its
corporate presentation on its website and presented the
presentation to investors. A copy of the presentation is attached
to this report as Exhibit 99.01. A copy of the presentation is
also available on the Companys website at www.neuralstem.com.
| Item 9.01 | Financial Statement and Exhibits. |
|
Exhibit No. |
Description |
|||
|
99.01 |
Corporate Presentation |
About Neuralstem, Inc. (NASDAQ:CUR)
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. (NASDAQ:CUR) Recent Trading Information
Neuralstem, Inc. (NASDAQ:CUR) closed its last trading session 00.00 at 4.90 with 32,021 shares trading hands.